News

Scientists have discovered a universal antibody that could help vaccine developers tackle foot-and-mouth disease virus (FMDV). Causing a highly contagious disease with high economic impact, FMDV affects susceptible cloven-hooved animals and fatalities may occur in young animals. Writing in the…

A strategic partnership between The Pirbright Institute and ProImmune aims to develop target-binding reagents that significantly accelerate research in animal health. Ankyrons™ are small, recombinant, target binding ankyrin repeat proteins developed by ProImmune. They are directly selected in vitro…

Scientists at The Pirbright Institute have generated a nearly complete genome assembly for an inbred domestic pig breed, enhancing the animal’s potential use as a biomedical model for better human and animal health. Derived from the domestic Large White pig breed, the highly inbred Babraham pig is…

Scientists are to search for a proof-of-concept vaccine that can cut methane emissions in cattle. Supported by $9.4 million from the Bezos Earth Fund and led by researchers at The Pirbright Institute and the Royal Veterinary College (RVC), an international consortium will seek to build scientific…

Researchers from The Pirbright Institute working to improve vaccines for infectious bronchitis virus (IBV) have identified targets in the virus’s genetic code that could make vaccines safer. Better vaccines would have a huge impact on improving health and welfare of poultry and protect food security…

The Pirbright Institute has generated the first pig antibodies against swine influenza (flu) that protect against infection and recognise the same parts of the flu virus as human antibodies. This indicates they could be used to develop and assess human antibody therapies and their delivery methods…

Studies carried out by The Pirbright Institute and the University of Oxford have shown that Oxford’s new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this…

Severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2), the virus that causes COVID-19, is thought to have originated in bats, but how it jumped hosts to infect humans is unclear, as is the potential for the virus to infect other animal species. Researchers from The Pirbright Institute have…

Two recent studies from The Pirbright Institute and the University of Edinburgh’s Roslin Institute show that two vaccines against specific strains of infectious bronchitis virus (IBV) do not offer complete protection against a third strain, and that this may be partly down to the temperature range…

The Pirbright Institute, working in collaboration with the University of Oxford, have successfully shown that two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine produce a greater antibody response than a single dose in pigs. The emergence and subsequent spread of SARS-CoV-2 has caused a global…

Scientists at The Pirbright Institute have shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease (COVID-19), is able to enter cells using the receptors of multiple mammalian species. The broad host range of SARS-CoV-2 confirms the potential risk…

Differences in the host immune response may explain why cattle are less susceptible to peste des petits ruminants (PPR) than goats, according to a collaborative research effort by scientists at The Pirbright Institute and the Tamil Nadu Veterinary and Animal Sciences University (TANUVAS) in Chennai…